2025 was a defining year for the radiopharmaceutical industry. Innovation accelerated, investment deepened, and clinical development efforts advanced across therapeutic and diagnostic programs. Throughout this momentum, one trend became especially clear: radiopharma’s progress is shaped by the strength and maturity of its infrastructure.
Manufacturing capacity, supply chain resilience, CDMO expertise, and logistics all became central operational priorities. Programs with stronger operational alignment tended to encounter fewer disruptions and clearer pathways to scale. Where infrastructure was fragmented or reactive, teams often encountered delays, cost pressure, or rework.
In this review, we examine the major infrastructure themes of 2025, highlight both progress and challenges, and outline what sponsors and CDMOs should prioritize heading into 2026.
Radiopharmaceutical Infrastructure Gains in 2025 & the Push for Scalable Growth
The radiopharmaceutical sector achieved meaningful progress last year. The global radiopharma market was valued at approximately US $11.85 billion in 2024 and projected to reach US $13.21 billion in 2025. Meanwhile, the CDMO segment alone was expected to grow to US $3.1 billion in 2025 and climb to US $7.2 billion by 2034.
These numbers represent more than market demand—they signal tangible momentum in manufacturing scale-up, facility expansion, and supply chain investment. For example, new production facilities designed for higher throughput and modularity demonstrate that infrastructure has become strategic, not secondary.
However, much of the 2025 expansion centered on research-stage capabilities and new facility design rather than on fully operational, end-to-end readiness. The most resource-intensive components (shielded hot cells, licensed radiation suites, trained staff, and validated quality systems) lagged behind facility announcements. This reflects accelerating demand and underscores the ongoing need for infrastructure that is operationally ready.
Where Radiopharma Infrastructure Still Falls Short in Supply, Scale & Regulation
Despite progress, several structural bottlenecks remained:
- Supply-chain fragility
Key isotopes, precursor materials, and reagents often depend on a limited number of suppliers. Cross-border regulations, transportation constraints, and geopolitical uncertainty further complicate sourcing. - Manufacturing scale-up constraints
Radiopharmaceutical manufacturing involves short half-life isotopes, specialized shielding, and unique process flows. Scaling production efficiently while maintaining quality continues to be a challenge. - Regulatory and operational complexity
Radiopharmaceuticals combine elements of drug, device, and radioactive material regulations. Sponsors, CDMOs, and regulators must integrate manufacturing, quality, and logistics into unified workflows to avoid fragmentation. - Workforce specialization and operational costs
Radiopharmaceutical manufacturing depends on trained experts in radiation safety, hot-lab operation, analytical quality, and isotope handling. Recruiting and retaining these teams takes time, and maintaining compliant facilities requires sustained investment. Even organizations with adequate facility footprints often need to expand training programs, safety culture, and operational support to scale reliably.
Additional capacity alone rarely resolves systemic challenges. Programs that progressed more reliably emphasized early alignment across manufacturing, supply chain, and regulatory operations.
Key Lessons for Radiopharma Sponsors & CDMOs from 2025
Teams that approached infrastructure as a strategic function, rather than a late-stage activity, reported more predictable development paths. Key lessons that emerged included:
- Engage CDMOs early
Partners with radiopharma manufacturing and regulatory experience provide critical input during process design and analytical planning, not only during technology transfer. - Build redundancy into the supply chain
With limited suppliers for isotopes and precursor reagents, qualifying alternates reduces vulnerability to transport, licensing, or availability constraints. - Integrate manufacturing, logistics, and regulatory planning
Programs that synchronized these efforts earlier in development demonstrated smoother IND progression and fewer downstream disruptions.
2026 Radiopharma Outlook on Infrastructure & Manufacturing Priorities
As the industry moves into 2026, several trends will define the next wave of progress:
- Next-gen isotopes and alpha-emitters
As isotopes such as Ac-225 and Pb-212 gain traction, organizations are investing in infrastructure capable of handling their manufacturing, safety, and regulatory requirements. - Modular and flexible manufacturing
Modular and flexible manufacturing, supported by automation, digital twins, and traceability platforms, is increasingly prioritized because it allows programs to scale without redesigning core infrastructure. Recent CDMO market analyses also point to modularity as a critical response to capacity constraints and evolving modality needs. - Supply chain localization and resilience
With international logistics tightening, regional diversification and more localized isotope sourcing are gaining emphasis. - Regulatory evolution
Regulators are updating expectations around manufacturing readiness, quality controls, and dose optimization. Infrastructure must evolve accordingly to meet these emerging standards. Together, these developments signal a more mature, data-driven era for radiopharma manufacturing.
Organizations that align with these priorities now will be positioned for faster, more reliable growth in 2026 and beyond.
Building Radiopharma Infrastructure Readiness: What to Do Now
Infrastructure readiness will determine which programs advance efficiently and which fall behind. Four practical steps can help ensure your program’s readiness:
- Select a CDMO with proven radiopharma experience, scalable infrastructure, and regulatory expertise.
- Audit isotope and precursor supply chains for single points of failure, and qualify alternate sources.
- Develop a manufacturing plan that includes scale-up, tech transfer, and regulatory preparedness from the outset.
- Align manufacturing, logistics, and regulatory teams early in development to minimize later friction.
Why Early CDMO Collaboration Is Essential to Radiopharma Infrastructure Success
In radiopharma, infrastructure strategy is not optional; it is foundational. Misalignment in supply chains, analytics, or scale-up can result in material delays. Partnering early with a CDMO experienced in radiochemistry, regulatory pathways, and manufacturing complexity is one of the most effective ways to support development continuity.
At Nucleus RadioPharma, we provide end-to-end development and manufacturing support built around radiopharma’s unique demands. Our integrated approach to isotope expertise, regulatory alignment, and infrastructure scalability ensures sponsors move from discovery to delivery with confidence.
If you are advancing a next-generation radiopharmaceutical program, connect with us early to build an infrastructure framework that supports speed, compliance, and scalability.